The Convidecia vaccine, of which a first batch of 200,000 doses arrived in the country this Friday, is an immunizer developed by the Chinese laboratory Cansino Biologics Inc that is applied in a single dose and that, after 28 days, had a higher efficacy 65% against symptomatic covid-19 and more than 90% against severe disease. However, the laboratory has not yet released updated data on the spread of the delta variant.
Meanwhile, after 28 days, it presented the same efficacy percentages, although with slight variations. In the phase III clinical trial of Ad5-nCoV (its name), more than 40,000 volunteers have been vaccinated at 78 clinical trial centers in five countries on three continents. The most common adverse reactions after inoculation were fever, redness, swelling, and pain at the vaccination site. According to its developers, a reaction can usually ease itself in 96 hours and no special treatment is required.
It is a vaccine that uses the human adenovirus that causes the common cold as a viral vector to transport the spike protein of the coronavirus. The vaccine needs a temperature of 2 ° to 8 ° Celsius for its conservation, which implies an advantage for logistics. Chile was the first South American country to approve its use. It was followed by Mexico, Pakistan, China and Hungary.
As explained, the 200,000 doses arriving from Qatar are part of the first game of a contract that contemplates the shipment of 5.4 million doses over the course of this year, as anticipated days ago in a press conference by the Minister of Cheers, Carla Vizzotti.
Since the beginning of the campaign, Argentina received almost 43 million vaccines, of which 14.7 million correspond to Sinopharm; 11.8 million to Sputnik V (about nine million from component 1 and about two million from component 2); almost 10 million from AstraZeneca and Oxford (whose active principle was produced in Argentina); 3.5 million Moderna; 1.9 million from AstraZeneca by the World Health Organization COVAX mechanism and 580,000 from AstraZeneca produced in India under the Covishield name.